The Wegovy FDA prescribing information lists nausea, vomiting, diarrhea, constipation, and abdominal pain as the most common adverse reactions, with rates highest during titration [3]
Carnivore diets contain virtually no dietary fiber, which may contribute to: Constipation Altered gut microbiome diversity Digestive discomfort in some individuals Keto vs
Insurance coverage for compounded tirzepatide varies by plan, and many plans may not cover compounded medications
Assuming Eli Lilly follows a similar timeline to tirzepatide, the earliest possible FDA approval for retatrutide would likely occur in late 2027 or 2028, depending on Phase 3 trial results and regulatory review timelines
Many GLP-1 patients (55.7%) lost over 10% of their body weight, while only 13.7% of metformin patients reached that threshold